Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Open Access
Abstract
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.Keywords
Funding Information
- American College of Rheumatology Research and Education Foundation (N/A)
- European Alliance of Associations for Rheumatology (N/A)
This publication has 35 references indexed in Scilit:
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseasesThe Lancet Rheumatology, 2021
- Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection ( PASC ) After SARS-Cov-2 VaccinationmedRxiv, 2021
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and ReinfectionClinical Infectious Diseases, 2021
- Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent SymptomsFrontiers in Microbiology, 2021
- Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infectionNature Communications, 2021
- A Multicenter Cohort Study From India of 75 Kidney Transplants in Recipients Recovered After COVID-19Transplantation, 2021
- Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: A systematic reviewAmerican Journal of Otolaryngology, 2021
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised HostNew England Journal of Medicine, 2020
- Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysisEBioMedicine, 2020